• 信息
  • 详情
  • 联系
  • 推荐
分享好友 产品首页 产品分类 切换频道
1/5
Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF  25 UG图1

Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF 25 UG

2024-11-24 19:24IP属地 广东省东莞市 电信00留言

8487-T4

 

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.


Reconstitution Reconstitute at 100 μg/mL in PBS.



Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.


Stability & Storage:       Use a manual defrost freezer and avoid repeated freeze-thaw cycles.      

  • 12 months from date of receipt, -20 to -70 °C as supplied.

  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.

  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


Background: LILRB5/CD85c/LIR-8

LIR-8, also known as CD85c and LILRB5, belongs to a family of transmembrane glycoproteins that negatively regulate immune cell activation (1). Mature human  
LIR-8 consists of a 435 amino acid (aa) extracellular domain with four Ig-like domains, a 21 aa transmembrane segment, and a 111 aa cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). Alternative splicing of human LIR-8 generates an isoform that lacks the second Ig-like domain. LIR-8 is expressed on NK cells and in the tryptic granules of mast cells (2, 3). Following cell activation and degranulation, it is present on the mast cell surface (3). Activated mast cells may also release soluble forms of LIR-8 (3). Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (4), R&D Systems in-house testing indicates that LIR-8 binds to Angiopoietin-like 7.

举报
收藏 0
评论 0
联系方式